Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Histalos, Lecisyn, Lecivriens, Levocetilerg, Levocetirizin, Xyzall; Belgium: Levocetirizine, Xyzall; Bulgaria: Xyzal; Cyprus: Xyzall; Czech Republic: Cezera, Lavaz, Lecivriens, Levocetirizin, Levozine, Sintir, Volnostin, Xyzal, Zenaro; Denmark: Levazyr, Levocetirizin, Xyzal; Estonia: Levocetirizine, Xyzal; Finland: Lecisyne, Lecivriens, Levazyr, Levocetilerg, Levocetirizin, Levocetirizine, Nocedan, Xyzal; France: Levocetirizine, Xyzal; Germany: Levocetirizin, Sopras, Xusal, Xyzal; Greece: Xozal; Hungary: Xyzal; Ireland: Levocetirizine, Muntel, Rinozal, Xyzall; Italy: Xyzall; Latvia: Levocetirizine, Xyzal, Zenaro; Lithuania: Levocetirizine, Xyzal; Luxembourg: Xyzall; Malta: Xyzal; Netherlands: Levocetirizine, Xyzal; Poland: Cezera, Xyzal; Portugal: Levocetirizina, Levrix, Xyzal; Romania: Cezera, Lerazin, Levocetirizina, Xyzal; Slovakia: Cezera, Levocetirizin, Levocetirizine, Xyzal, Zenaro; Slovenia: Xyzal; Spain: Levocetirizina, Muntel, Xazal; Sweden: Xyzall; UK: Xyzal.

North America

USA: Xyzal.

Latin America

Argentina: Analerg, Cetimer L, Levomine, Supraler; Brazil: Zyxem; Mexico: Xuzal, Zyxem.

Drug combinations


Levocetirizine Dihydrochloride: C~21~H~25~ClN~2~O~3~ 2HCl. Mw: 461.80. (1) Acetic acid, [2-[4-[(R)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride; (2)(2-{4-[(R)-(4-Chlorophenyl)phenylmethyl]piperazin-1-yl}ethoxy)acetic acid dihydrochloride. CAS-130018-87-0 (2007).

Pharmacologic Category

Second Generation Antihistamines; Histamine H~1~ Antagonist. (ATC-Code: R06AE09).

Mechanism of action

Antihistamine which selectively competes with histamine for H~1~-receptor sites on effector cells in GI tract, blood vessels, and respiratory tract.

Therapeutic use

Relief of symptoms of perennial and seasonal allergic rhinitis. Treatment of skin manifestations (uncomplicated) of chronic idiopathic urticaria.

Pregnancy and lactiation implications

Levocetirizine not teratogenic in animal studies. Use during pregnancy only if clearly needed. Use not recommended while breast-feeding.

Unlabeled use


Hypersensitivity to levocetirizine, cetirizine, or any component of the formulation. End-stage renal disease. Hemodialysis. Children 6-11 years of age with renal impairment.

Warnings and precautions

May cause CNS depression. Use with caution in adults with mild-to-moderate renal impairment (this drug excreted primarily by kidneys). Use contraindicated in end-stage renal disease (CrCl <10 mL/minute), patients undergoing hemodialysis, and in children 6-11 years of age with renal impairment. Use with caution in the elderly. Not FDA approved for use in children <6 years of age.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart